Cantor Fitzgerald Maintains Celldex Therapeutics (CLDX) Overweight Recommendation
Fintel reports that on May 5, 2023, Cantor Fitzgerald maintained coverage of Celldex Therapeutics (NASDAQ:CLDX) with a Overweight recommendation. Analyst Price Forecast Suggests 103.82% Upside As of April 24, 2023, the average one-year price target for Celldex Therapeutics is 67.83. The forecasts range from a low of 55.55 to a…
bubmagMay 6, 2023